DK2334705T3 - Biologiske produkter - Google Patents
Biologiske produkter Download PDFInfo
- Publication number
- DK2334705T3 DK2334705T3 DK09736624.9T DK09736624T DK2334705T3 DK 2334705 T3 DK2334705 T3 DK 2334705T3 DK 09736624 T DK09736624 T DK 09736624T DK 2334705 T3 DK2334705 T3 DK 2334705T3
- Authority
- DK
- Denmark
- Prior art keywords
- fab
- antibody
- seq
- dab
- sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
Claims (9)
1. Multivalent antistoffusionsprotein, som omfatter et Fab- eller Fab'-fragment, med en første specificitet til et antigen af interesse og som yderligere omfatter to enkelt-domæne-antistoffer (dAb) med specificitet til et andet antigen af interesse, hvor de to enkelt-domæne-antistoffer er bundet af en disulfidbinding og hvor de to enkelt-domæne-antistoffer er et VH/VL-par og VH-dAb'et er genetisk splejset sammen, direkte eller via en linker til den C-terminale ende af Fab- eller Fab’-tung-kæden og VL-dAb'et er genetisk splejset sammen, direkte eller via en linker til den C-terminale ende af Fab- eller Fab'-let-kæden.
2. Multivalent antistoffusionsprotein ifølge krav 1, hvor det første antigen og andet antigen er forskellige præparater.
3. Multivalent antistoffusionsprotein ifølge krav 1 eller krav 2, hvor det andet antigen er albumin.
4. Multivalent antistoffusionsprotein ifølge krav 3, hvor albuminet er humant serumalbumin.
5. Dobbelt specificitets antistoffusionsprotein ifølge krav 1, omfattende et Fab- eller Fab'-fragment, med en første specificitet til et antigen af interesse og som yderligere omfatter to enkelt-domæne-antistoffer (dAb) med specificitet til et andet antigen af interesse, som binder humant serumalbumin og hvor de to enkelt-domæne-antistoffer er bundet af en disulfidbinding og ét af enkelt-domæne-antistofferne er et tung-kæde-VFI-enkelt-domæne-anti-stof, som omfatter mindst én af en CDR, der har sekvensen givet på figur 5 (e) SEQ ID NO:56 eller figur 5 (k) SEQ ID NO:62 for CDR-H1, en CDR, der har sekvensen givet på figur 5(f) SEQ ID NO:57 eller figur 5 (1) SEQ ID NO:63 for CDR-H2 og en CDR, der har sekvensen givet på figur 5 (g) SEQ ID NO:58 eller figur 5 (m) SEQ ID NO:64 for CDR-H3.
6. Dobbelt specificitets antistoffusionsprotein ifølge krav 1, omfattende et Fab- eller Fab'-fragment, med en første specificitet til et antigen af interesse og som yderligere omfatter to enkelt-domæne-antistoffer (dAb) med specificitet til et andet antigen af interesse, som binder humant serumalbumin og hvor de to enkelt-domæne-antistoffer er bundet af en disulfidbinding og ét af enkelt-domæne-antistofferne er et let-kæde-VL-enkelt-domæne-antistof, som omfatter mindst én af en CDR, der har sekvensen givet på figur 5 (h) SEQ ID NO:59 eller figur 5 (n) SEQ ID NO:65 for CDR-L1, en CDR, der har sekvensen givet på figur 5(i) SEQ ID NO:60 eller figur 5 (o) SEQ ID NO:66 for CDR-L2 og en CDR, der har sekvensen givet på figur 5 (j) SEQ ID NO:61 eller figur 5 (p) SEQ ID NO:67 for CDR-L3.
7. Dobbelt specificitets antistoffusionsprotein ifølge krav 1, omfattende et Fab- eller Fab'-fragment, med en første specificitet til et antigen af interesse og som yderligere omfatter to enkelt-domæne-antistoffer (dAb) med specificitet til et andet antigen af interesse, som binder humant serumalbumin og hvor de to enkelt-domæne-antistoffer er bundet af en disulfidbinding og ét af enkelt-domæne-antistofferne er et tung-kæde-VFi-enkelt-domæne-anti-stof, som omfatter sekvensen givet i SEQ ID NO: 56 for CDRH1, sekvensen givet i SEQ ID NO: 57 for CDRFI2 og sekvensen givet i SEQ ID NO: 58 for CDRH3 og det andet enkelt domæne-antistof er et let-kæde-VL-enkelt-domæne-antistof, som omfatter sekvensen givet i SEQ ID NO: 59 for CDRL1, sekvensen givet i SEQ ID NO: 60 for CDRL2 og sekvensen givet i SEQ ID NO: 61 for CDRL3.
8. Farmaceutisk sammensætning omfattende et multivalent eller dobbelt specificitets antistoffusionsprotein ifølge et hvilket som helst af krav 1 til 7 i forbindelse med ét eller flere farmaceutisk acceptable bærestoffer, excipienser eller fortyndingsmidler.
9. Multivalent eller dobbelt specificitets antistoffusionsprotein ifølge et hvilket som helst af krav 1 til 8 til anvendelse i terapi.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0817704A GB0817704D0 (en) | 2008-09-26 | 2008-09-26 | Biological products |
GB0905314A GB0905314D0 (en) | 2009-03-26 | 2009-03-26 | Biological products |
PCT/GB2009/002310 WO2010035012A1 (en) | 2008-09-26 | 2009-09-25 | Biological products |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2334705T3 true DK2334705T3 (da) | 2017-03-27 |
Family
ID=41664777
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK09736624.9T DK2334705T3 (da) | 2008-09-26 | 2009-09-25 | Biologiske produkter |
Country Status (17)
Country | Link |
---|---|
US (2) | US10407513B2 (da) |
EP (1) | EP2334705B1 (da) |
JP (2) | JP6063122B2 (da) |
CN (2) | CN102164965B (da) |
BR (1) | BRPI0918947A2 (da) |
CA (1) | CA2737241C (da) |
CY (1) | CY1118713T1 (da) |
DK (1) | DK2334705T3 (da) |
EA (1) | EA201100527A1 (da) |
ES (1) | ES2620603T3 (da) |
HR (1) | HRP20170374T1 (da) |
HU (1) | HUE033438T2 (da) |
LT (1) | LT2334705T (da) |
PL (1) | PL2334705T3 (da) |
PT (1) | PT2334705T (da) |
SI (1) | SI2334705T1 (da) |
WO (1) | WO2010035012A1 (da) |
Families Citing this family (150)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2757931C (en) | 2009-04-07 | 2019-03-26 | Roche Glycart Ag | Trivalent, bispecific antibodies |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
WO2011030107A1 (en) | 2009-09-10 | 2011-03-17 | Ucb Pharma S.A. | Multivalent antibodies |
GB201005063D0 (en) * | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
GB0922435D0 (en) | 2009-12-22 | 2010-02-03 | Ucb Pharma Sa | Method |
US8734798B2 (en) | 2009-10-27 | 2014-05-27 | Ucb Pharma S.A. | Function modifying NAv 1.7 antibodies |
US9234037B2 (en) | 2009-10-27 | 2016-01-12 | Ucb Biopharma Sprl | Method to generate antibodies to ion channels |
GB0922434D0 (en) | 2009-12-22 | 2010-02-03 | Ucb Pharma Sa | antibodies and fragments thereof |
GB0920127D0 (en) | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
GB0920324D0 (en) * | 2009-11-19 | 2010-01-06 | Ucb Pharma Sa | Antibodies |
TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
WO2012009544A2 (en) * | 2010-07-14 | 2012-01-19 | Amgen Inc. | Domain insertion immunoglobulin |
KR101586128B1 (ko) * | 2010-08-24 | 2016-01-15 | 에프. 호프만-라 로슈 아게 | 디술피드 안정화 ― Fv 단편을 포함하는 이중특이적 항체 |
RU2013110876A (ru) * | 2010-08-24 | 2014-09-27 | Рош Гликарт Аг | Активируемые биспецифические антитела |
US9598499B2 (en) | 2010-12-30 | 2017-03-21 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Antigen binding formats for use in therapeutic treatments or diagnostic assays |
GB201100282D0 (en) | 2011-01-07 | 2011-02-23 | Ucb Pharma Sa | Biological methods |
US10208349B2 (en) | 2011-01-07 | 2019-02-19 | Ucb Biopharma Sprl | Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy |
WO2012095662A1 (en) | 2011-01-14 | 2012-07-19 | Ucb Pharma S.A. | Antibody molecules which bind il-17a and il-17f |
SG194472A1 (en) * | 2011-01-28 | 2013-12-30 | Ca Nat Research Council | Engineering of immunoglobulin domains |
CA2828347A1 (en) * | 2011-03-10 | 2012-09-13 | Hco Antibody, Inc. | Bispecific three-chain antibody-like molecules |
CN103797367B (zh) * | 2011-09-06 | 2016-05-25 | 马克斯.普朗克促进科学协会 | 用于分析生物大分子复合物的方法及其用途 |
SI2758432T1 (sl) | 2011-09-16 | 2019-07-31 | Ucb Biopharma Sprl | Nevtralizirajoča protitelesa proti glavnim eksotoksinom TCDA in TCDB iz clostridium difficile |
PT2776466T (pt) * | 2011-11-11 | 2017-11-30 | Ucb Biopharma Sprl | Anticorpos de ligação a albumina e seus fragmentos de ligação |
UA112203C2 (uk) | 2011-11-11 | 2016-08-10 | Юсб Фарма С.А. | Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини |
GB201208367D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Biological product |
GB201208370D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
MX2014014804A (es) | 2012-06-27 | 2015-02-12 | Hoffmann La Roche | Metodo para la elaboracion de conjugados de la region fc de anticuerpos que comprenden por lo menos una entidad de union que se une especificamente a un objetivo y usos del mismo. |
WO2014001324A1 (en) | 2012-06-27 | 2014-01-03 | Hoffmann-La Roche Ag | Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof |
GB201223276D0 (en) | 2012-12-21 | 2013-02-06 | Ucb Pharma Sa | Antibodies and methods of producing same |
EP2970449B1 (en) * | 2013-03-15 | 2019-09-25 | Amgen Research (Munich) GmbH | Single chain binding molecules comprising n-terminal abp |
GB201315487D0 (en) | 2013-08-30 | 2013-10-16 | Ucb Pharma Sa | Antibodies |
MX371328B (es) * | 2013-08-30 | 2020-01-27 | Aprilbio Co Ltd | Constructo de fusion de la fraccion efectora del fragmento de union a antigeno (fab) de anti-albumina de suero y su metodo de preparacion. |
CA3183645A1 (en) | 2013-10-25 | 2015-04-30 | Psioxus Therapeutics Limited | Oncolytic adenoviruses armed with heterologous genes |
US20160280787A1 (en) | 2013-11-11 | 2016-09-29 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule containing modified antibody variable region |
GB201320066D0 (en) | 2013-11-13 | 2013-12-25 | Ucb Pharma Sa | Biological products |
US8986694B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Targeting human nav1.7 variants for treatment of pain |
US9914769B2 (en) | 2014-07-15 | 2018-03-13 | Kymab Limited | Precision medicine for cholesterol treatment |
US9045545B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision medicine by targeting PD-L1 variants for treatment of cancer |
US8992927B1 (en) | 2014-07-15 | 2015-03-31 | Kymab Limited | Targeting human NAV1.7 variants for treatment of pain |
US9067998B1 (en) | 2014-07-15 | 2015-06-30 | Kymab Limited | Targeting PD-1 variants for treatment of cancer |
CN110092837B (zh) * | 2014-02-24 | 2024-01-02 | 武田有限公司 | Uti融合蛋白 |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
GB201406608D0 (en) | 2014-04-12 | 2014-05-28 | Psioxus Therapeutics Ltd | Virus |
GB201409558D0 (en) | 2014-05-29 | 2014-07-16 | Ucb Biopharma Sprl | Method |
GB201411320D0 (en) | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
US9139648B1 (en) | 2014-07-15 | 2015-09-22 | Kymab Limited | Precision medicine by targeting human NAV1.9 variants for treatment of pain |
GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
GB201412659D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
US11154615B2 (en) | 2014-11-11 | 2021-10-26 | Chugai Seiyaku Kabushiki Kaisha | Library of antigen-binding molecules including modified antibody variable region |
CN107001482B (zh) | 2014-12-03 | 2021-06-15 | 豪夫迈·罗氏有限公司 | 多特异性抗体 |
GB201506870D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
GB201506869D0 (en) * | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
JP2018515082A (ja) | 2015-04-30 | 2018-06-14 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 代謝障害を処置するための抗ap2抗体及び抗原結合剤 |
GB201508180D0 (en) | 2015-05-13 | 2015-06-24 | Ucb Biopharma Sprl | Antibodies |
KR20180012279A (ko) | 2015-05-27 | 2018-02-05 | 유씨비 바이오파마 에스피알엘 | 신경 질환의 치료를 위한 방법 |
WO2016192613A1 (zh) * | 2015-06-01 | 2016-12-08 | 中山大学 | 具有融合至常规Fab片段的单域抗原结合片段的二价抗体 |
EA037092B1 (ru) | 2015-07-06 | 2021-02-04 | Юсб Биофарма Срл | Тау-связывающие антитела |
US10344081B2 (en) | 2015-07-06 | 2019-07-09 | Ucb Biopharma Sprl | Tau-binding antibodies |
GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
ES2885476T3 (es) | 2015-10-05 | 2021-12-13 | Ucb Biopharma Sprl | Firmas moleculares para uso en diagnóstico y análisis de respuesta al tratamiento de enfermedades autoinmunes |
SG10202112586WA (en) | 2015-10-27 | 2021-12-30 | UCB Biopharma SRL | Methods of treatment using anti-il-17a/f antibodies |
GB201521383D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl And Ucb Celltech | Method |
GB201521382D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
GB201521391D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
GB201521389D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Method |
GB201521393D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
GB201522394D0 (en) | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibodies |
GB201602414D0 (en) | 2016-02-10 | 2016-03-23 | Nascient Ltd | Biological materials and uses thereof |
WO2017191062A1 (en) | 2016-05-01 | 2017-11-09 | Ucb Biopharma Sprl | Affinity engineered serum protein carrier binding domain |
GB201610198D0 (en) | 2016-06-10 | 2016-07-27 | Ucb Biopharma Sprl | Anti-ige antibodies |
EP3503919B1 (en) | 2016-08-29 | 2024-04-10 | Akamis Bio Limited | Adenovirus armed with bispecific t cell engager |
WO2018083257A1 (en) | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
WO2018083258A1 (en) | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding at least three transgenes |
EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
RU2022101604A (ru) | 2016-12-07 | 2022-03-29 | Аблинкс Нв | Улучшенные отдельные вариабельные домены иммуноглобулина, связывающиеся с сывороточным альбумином |
SG10202108972RA (en) * | 2017-01-17 | 2021-09-29 | Ablynx Nv | Improved serum albumin binders |
BR112019014600A2 (pt) * | 2017-01-17 | 2020-02-18 | Ablynx N.V. | Ligantes de albumina sérica melhorados |
WO2018183366A1 (en) | 2017-03-28 | 2018-10-04 | Syndax Pharmaceuticals, Inc. | Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy |
WO2018213665A1 (en) | 2017-05-19 | 2018-11-22 | Syndax Pharmaceuticals, Inc. | Combination therapies |
HRP20230812T1 (hr) | 2017-06-01 | 2023-11-24 | Akamis Bio Limited | Onkolitički virus i metoda |
JP7130678B2 (ja) * | 2017-06-05 | 2022-09-05 | ヌマブ セラピューティクス アクチェンゲゼルシャフト | 新規抗hsa抗体 |
WO2018224439A1 (en) * | 2017-06-05 | 2018-12-13 | Numab Innovation Ag | Novel anti-hsa antibodies |
US20200165347A1 (en) | 2017-06-30 | 2020-05-28 | Aslan Pharmaceuticals Pte Ltd | Method of treatment using il-13r antibody |
EP3470426A1 (en) | 2017-10-10 | 2019-04-17 | Numab Therapeutics AG | Multispecific antibody |
EP3694873A1 (en) | 2017-10-10 | 2020-08-19 | Numab Therapeutics AG | Multispecific antibody |
JP7357616B2 (ja) | 2017-12-05 | 2023-10-06 | 中外製薬株式会社 | Cd3およびcd137に結合する改変された抗体可変領域を含む抗原結合分子 |
JP2021506310A (ja) | 2017-12-22 | 2021-02-22 | アルゲン−エックス ビーブイビーエー | 二重特異性抗原結合コンストラクト |
GB201802487D0 (en) | 2018-02-15 | 2018-04-04 | Argenx Bvba | Cytokine combination therapy |
GB201811368D0 (en) * | 2018-07-11 | 2018-08-29 | Ucb Biopharma Sprl | Antibody |
CA3110013A1 (en) | 2018-08-21 | 2020-02-27 | Citryll B.V. | Antibodies binding to citrullinated histone 2a and/or 4 |
JP2022501325A (ja) * | 2018-09-28 | 2022-01-06 | 中外製薬株式会社 | 改変された抗体可変領域を含む抗原結合分子 |
WO2020079086A1 (en) | 2018-10-16 | 2020-04-23 | UCB Biopharma SRL | Method for the treatment of myasthenia gravis |
GB201817309D0 (en) | 2018-10-24 | 2018-12-05 | Ucb Biopharma Sprl | Antibodies |
GB201817311D0 (en) | 2018-10-24 | 2018-12-05 | Ucb Biopharma Sprl | Antibodies |
GB2596411B (en) * | 2018-10-29 | 2023-09-20 | Tigatx Inc | Compositions and methods comprising IgA antibody constructs |
JP2022528324A (ja) | 2019-03-26 | 2022-06-10 | アスラン ファーマシューティカルズ ピーティーイー リミテッド | 抗il13r抗体またはその結合フラグメントを用いた治療 |
JP2022528067A (ja) | 2019-03-27 | 2022-06-08 | ユーエムシー ユトレヒト ホールディング ビー.ブイ. | 工学的に操作されたIgA抗体および使用方法 |
EP3816185A1 (en) | 2019-11-04 | 2021-05-05 | Numab Therapeutics AG | Multispecific antibody directed against pd-l1 and a tumor-associated antigen |
GB201919058D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Multi-specific antibodies |
GB201919062D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Antibody |
GB201919061D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Multi-specific antibody |
KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
GB202001447D0 (en) | 2020-02-03 | 2020-03-18 | Ucb Biopharma Sprl | Antibodies |
US20230151108A1 (en) | 2020-02-13 | 2023-05-18 | UCB Biopharma SRL | Bispecific antibodies against cd9 and cd137 |
ES2975410T3 (es) | 2020-02-13 | 2024-07-05 | UCB Biopharma SRL | Anticuerpos biespecíficos que se unen a HVEM y CD9 |
US20230151109A1 (en) | 2020-02-13 | 2023-05-18 | UCB Biopharma SRL | Bispecific antibodies against cd9 |
EP4103610A1 (en) | 2020-02-13 | 2022-12-21 | UCB Biopharma SRL | Anti cd44-ctla4 bispecific antibodies |
WO2021160267A1 (en) | 2020-02-13 | 2021-08-19 | UCB Biopharma SRL | Bispecific antibodies against cd9 and cd7 |
CN115210257A (zh) | 2020-02-21 | 2022-10-18 | 江苏恒瑞医药股份有限公司 | 抗il-2抗体、其抗原结合片段及其医药用途 |
KR20220160069A (ko) | 2020-03-27 | 2022-12-05 | 유씨비 바이오파마 에스알엘 | 자율적 노브 도메인 펩티드 |
AU2021250186A1 (en) | 2020-03-31 | 2022-12-01 | Chugai Seiyaku Kabushiki Kaisha | DLL3-targeting multispecific antigen-binding molecules and uses thereof |
CN115397860A (zh) | 2020-05-14 | 2022-11-25 | 江苏恒瑞医药股份有限公司 | 抗cd25抗体、其抗原结合片段及其医药用途 |
EP3915580A1 (en) | 2020-05-29 | 2021-12-01 | Numab Therapeutics AG | Multispecific antibody |
EP4174092A4 (en) * | 2020-06-30 | 2024-03-20 | Harbour Biomed (Shanghai) Co., Ltd | MULTI-SPECIFIC IMMUNE CELL ENGAGEMENT BINDING PROTEIN, PRODUCTION THEREOF AND USE THEREOF |
US20230220111A1 (en) | 2020-07-02 | 2023-07-13 | Beijing Tuo Jie Biopharmaceutical Co. Ltd. | Anti-fxi/fxia antibody, antigen-binding fragment thereof, and pharmaceutical use thereof |
KR20230044275A (ko) | 2020-07-27 | 2023-04-03 | 투오지에 바이오텍 (상하이) 컴퍼니 리미티드 | 항-cd79b 항체-약물 접합체, 및 이의 제조 방법 및 이의 약학적 용도 |
GB202012326D0 (en) | 2020-08-07 | 2020-09-23 | Citryll B V | Diagnostic |
CA3198049A1 (en) | 2020-10-15 | 2022-04-21 | UCB Biopharma SRL | Binding molecules that multimerise cd45 |
EP3988568A1 (en) | 2020-10-21 | 2022-04-27 | Numab Therapeutics AG | Combination treatment |
JP2023550596A (ja) | 2020-11-02 | 2023-12-04 | ユーシービー バイオファルマ エスアールエル | 運動ニューロン神経変性障害の治療のための抗trem1中和抗体の使用 |
EP4255926A1 (en) | 2020-12-07 | 2023-10-11 | UCB Biopharma SRL | Multi-specific antibodies and antibody combinations |
CN116802211A (zh) | 2020-12-07 | 2023-09-22 | Ucb生物制药有限责任公司 | 针对白介素-22的抗体 |
EP4267185A1 (en) * | 2020-12-23 | 2023-11-01 | Lumen Bioscience, Inc. | Constructs comprising single domain vhh antibodies against sars-cov-2 |
JP2024504471A (ja) | 2021-02-02 | 2024-01-31 | ヌマブ セラピューティックス アーゲー | Ror1およびcd3に対する特異性を有する多重特異性抗体 |
GB202102227D0 (en) | 2021-02-17 | 2021-03-31 | UCB Biopharma SRL | Antibodies |
AU2022263683A1 (en) | 2021-04-25 | 2023-11-23 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Anti-masp2 antibody, antigen-binding fragment thereof and medical use thereof |
CA3218933A1 (en) | 2021-05-03 | 2022-11-10 | UCB Biopharma SRL | Antibodies |
EP4085973A1 (en) | 2021-05-04 | 2022-11-09 | Citryll B.V. | Inhibition of eosinophil extracellular traps |
KR20240005856A (ko) | 2021-05-04 | 2024-01-12 | 씨트릴 비.브이. | 세포 외 트랩 억제 |
CA3223842A1 (en) | 2021-06-28 | 2023-01-05 | Yuan Lin | Anti-cd40 antibody, antigen-binding fragment and medical use thereof |
GB202111905D0 (en) | 2021-08-19 | 2021-10-06 | UCB Biopharma SRL | Antibodies |
WO2023025249A1 (zh) | 2021-08-25 | 2023-03-02 | 江苏恒瑞医药股份有限公司 | 一种含融合蛋白的药物组合物 |
CA3231320A1 (en) | 2021-09-15 | 2023-03-23 | Zhiliang CAO | Protein specifically binding to pd-1 and pharmaceutical use thereof |
WO2023075702A1 (en) | 2021-10-29 | 2023-05-04 | Aslan Pharmaceuticals Pte Ltd | Anti-il-13r antibody formulation |
EP4183800A1 (en) | 2021-11-19 | 2023-05-24 | Medizinische Hochschule Hannover | Novel sars-cov-2 neutralizing antibodies |
US20230220115A1 (en) * | 2022-01-12 | 2023-07-13 | Biomolecular Holdings Llc | Tetrahedral antibodies |
WO2023140780A1 (en) | 2022-01-24 | 2023-07-27 | Aslan Pharmaceuticals Pte Ltd. | Method of treating inflammatory disease |
WO2023163659A1 (en) | 2022-02-23 | 2023-08-31 | Aslan Pharmaceuticals Pte Ltd | Glycosylated form of anti-il13r antibody |
CN114657125B (zh) * | 2022-04-29 | 2023-08-08 | 中国科学院海洋研究所 | 鲨鱼单个核细胞的分离方法、鲨鱼稀释液及其用途 |
WO2024038095A1 (en) | 2022-08-16 | 2024-02-22 | Iome Bio | NOVEL ANTI-RGMb ANTIBODIES |
WO2024043837A1 (en) | 2022-08-26 | 2024-02-29 | Aslan Pharmaceuticals Pte Ltd | High concentration anti-il13r antibody formulation |
WO2024050354A1 (en) | 2022-08-31 | 2024-03-07 | Washington University | Alphavirus antigen binding antibodies and uses thereof |
GB202214756D0 (en) | 2022-10-07 | 2022-11-23 | Univ Oxford Innovation Ltd | Product |
GB202216284D0 (en) | 2022-11-02 | 2022-12-14 | Ucl Business Ltd | Self-regulation |
WO2024115393A1 (en) | 2022-11-28 | 2024-06-06 | UCB Biopharma SRL | Treatment of fibromyalgia |
WO2024135812A1 (en) * | 2022-12-23 | 2024-06-27 | Chugai Seiyaku Kabushiki Kaisha | A polypeptide complex whose antigen-binding activity varies depending on the concentration of a plasma protein |
GB202403366D0 (en) | 2024-03-08 | 2024-04-24 | Univ Oxford Innovation Ltd | Product |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3785186T2 (de) | 1986-09-02 | 1993-07-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
US6267964B1 (en) * | 1989-08-01 | 2001-07-31 | Affibody Technology Sweden Ab | Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives |
DE4118120A1 (de) * | 1991-06-03 | 1992-12-10 | Behringwerke Ag | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung |
EP0617706B1 (en) | 1991-11-25 | 2001-10-17 | Enzon, Inc. | Multivalent antigen-binding proteins |
ATE149570T1 (de) | 1992-08-17 | 1997-03-15 | Genentech Inc | Bispezifische immunoadhesine |
GB9221657D0 (en) | 1992-10-15 | 1992-11-25 | Scotgen Ltd | Recombinant bispecific antibodies |
ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
WO1995009917A1 (en) | 1993-10-07 | 1995-04-13 | The Regents Of The University Of California | Genetically engineered bispecific tetravalent antibodies |
US5972901A (en) * | 1994-03-23 | 1999-10-26 | Case Western Reserve University | Serpin enzyme complex receptor--mediated gene transfer |
US5641870A (en) * | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US6239259B1 (en) * | 1996-04-04 | 2001-05-29 | Unilever Patent Holdings B.V. | Multivalent and multispecific antigen-binding protein |
ATE283925T1 (de) * | 1996-07-23 | 2004-12-15 | Tanox Pharma B V | Induzierung von t zell toleranz unter verwendung eines löslichen moleküls, dass gleichzeitig zwei kostimulierungswege blockieren kann |
EP1027439B1 (en) * | 1997-10-27 | 2010-03-17 | Bac Ip B.V. | Multivalent antigen-binding proteins |
EP1049787B1 (en) * | 1998-01-23 | 2004-11-24 | Vlaams Interuniversitair Instituut voor Biotechnologie | Multipurpose antibody derivatives |
DE19819846B4 (de) * | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
EP1089766B1 (en) * | 1998-06-22 | 2010-03-17 | Immunomedics, Inc. | Use of bi-specific antibodies for pre-targeting diagnosis and therapy |
US20060228364A1 (en) | 1999-12-24 | 2006-10-12 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
CA2921260A1 (en) | 1999-12-24 | 2001-06-28 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
AU2001247616B2 (en) | 2000-04-11 | 2007-06-14 | Genentech, Inc. | Multivalent antibodies and uses therefor |
DE10021678A1 (de) * | 2000-05-05 | 2002-04-18 | Stefan Duebel | Antikörperkonstrukte mit variablen Regionen |
EP1299419A2 (en) * | 2000-05-24 | 2003-04-09 | Imclone Systems, Inc. | Bispecific immunoglobulin-like antigen binding proteins and method of production |
CZ2003291A3 (cs) | 2000-06-29 | 2003-05-14 | Abbott Laboratories | Duálně specifické protilátky a způsoby jejich výroby a použití |
EP1294904A1 (en) | 2000-06-30 | 2003-03-26 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Heterodimeric fusion proteins |
US20020010334A1 (en) * | 2000-06-30 | 2002-01-24 | Xun Li | Processes to prepare pyrimidinediones |
ATE545703T1 (de) | 2000-07-25 | 2012-03-15 | Immunomedics Inc | Multivalentes zielbindendes protein |
EP1377306A1 (en) | 2001-03-09 | 2004-01-07 | Dyax Corp. | Serum albumin binding moieties |
AU2002319402B2 (en) * | 2001-06-28 | 2008-09-11 | Domantis Limited | Dual-specific ligand and its use |
ATE346866T1 (de) * | 2001-09-14 | 2006-12-15 | Affimed Therapeutics Ag | Multimerische, einzelkettige, tandem-fv- antikörper |
EP1576172A2 (en) | 2002-06-21 | 2005-09-21 | Dyax Corporation | Serum protein-associated target-specific ligands and identification method therefor |
CA2492092A1 (en) * | 2002-06-28 | 2004-01-08 | Greg Winter | Immunoglobin single variant antigen-binding domains and dual-specific constructs |
EP1545430A4 (en) | 2002-09-16 | 2006-01-04 | Elusys Therapeutics Inc | BISPECIFIC MOLECULE COMPRISING ANTI-CR1TICTIC ANTIBODY TO ANTIGENIC BINDING ANTIBODY FRAGMENT |
EP3299393A1 (en) | 2002-11-08 | 2018-03-28 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
JP2006523090A (ja) * | 2002-12-27 | 2006-10-12 | ドマンティス リミテッド | リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体 |
GB0230201D0 (en) * | 2002-12-27 | 2003-02-05 | Domantis Ltd | Retargeting |
GB0230203D0 (en) * | 2002-12-27 | 2003-02-05 | Domantis Ltd | Fc fusion |
CA2530388A1 (en) | 2003-06-27 | 2005-01-06 | Biogen Idec Ma Inc. | Modified binding molecules comprising connecting peptides |
DE602004017726D1 (de) * | 2003-06-30 | 2008-12-24 | Domantis Ltd | Pegylierte Single-domain-antikörper (dAb) |
JP5011277B2 (ja) * | 2005-04-06 | 2012-08-29 | アイビーシー・ファーマシューティカルズ・インコーポレーテッド | ホモダイマー、ホモテトラマーまたはダイマーのダイマーのからなる安定に連結された複合体を発生させるための方法および使用 |
ES2971647T3 (es) * | 2005-04-15 | 2024-06-06 | Macrogenics Inc | Diacuerpos covalentes y usos de los mismos |
EP1888641B1 (en) | 2005-05-18 | 2011-12-14 | Ablynx N.V. | Serum albumin binding proteins |
BRPI0615026A8 (pt) | 2005-08-19 | 2018-03-06 | Abbott Lab | imunoglobulina de domínio variável duplo e seus usos |
US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
GB0601513D0 (en) | 2006-01-25 | 2006-03-08 | Univ Erasmus Medical Ct | Binding molecules 3 |
CN101578298A (zh) * | 2006-01-24 | 2009-11-11 | 杜门蒂斯有限公司 | 结合il-4和/或il-13的配体 |
MX2008010561A (es) | 2006-02-15 | 2009-03-02 | Imclone Systems Inc | Anticuerpos funcionales. |
AU2007227292B2 (en) | 2006-03-17 | 2012-04-12 | Biogen Ma Inc. | Stabilized polypeptide compositions |
AU2007257692B2 (en) | 2006-06-12 | 2013-11-14 | Aptevo Research And Development Llc | Single-chain multivalent binding proteins with effector function |
AT503889B1 (de) | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | Multivalente immunglobuline |
CN101990439A (zh) * | 2007-07-06 | 2011-03-23 | 特鲁比昂药品公司 | 具有置于c末端的特异性结合结构域的结合肽 |
EP2014680A1 (en) | 2007-07-10 | 2009-01-14 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives |
EP2069401A4 (en) | 2007-07-31 | 2011-02-23 | Medimmune Llc | MULTISPECIENT EPITOP BINDING PROTEINS AND THEIR USE |
EP2532676B1 (en) | 2007-08-15 | 2017-03-22 | Bayer Pharma Aktiengesellschaft | Protease-regulated antibody |
CA2700714C (en) * | 2007-09-26 | 2018-09-11 | Ucb Pharma S.A. | Dual specificity antibody fusions |
EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
US8975382B2 (en) | 2007-11-27 | 2015-03-10 | Ablynx N.V. | Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors |
DE112008003232T5 (de) | 2007-11-30 | 2011-02-24 | Glaxo Group Limited, Greenford | Antigen-Bindungskonstrukte |
US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
JP2011515073A (ja) * | 2008-02-20 | 2011-05-19 | ジーツー インフラメイション プロプライエタリー リミテッド | ヒト化抗C5aR抗体 |
CN102300879A (zh) | 2008-12-04 | 2011-12-28 | 雅培制药有限公司 | 双重可变结构域免疫球蛋白及其用途 |
CA2761233A1 (en) | 2009-05-27 | 2010-12-02 | F. Hoffmann-La Roche Ag | Tri- or tetraspecific antibodies |
WO2011030107A1 (en) | 2009-09-10 | 2011-03-17 | Ucb Pharma S.A. | Multivalent antibodies |
GB201005063D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
-
2009
- 2009-09-25 JP JP2011528417A patent/JP6063122B2/ja not_active Expired - Fee Related
- 2009-09-25 SI SI200931626A patent/SI2334705T1/sl unknown
- 2009-09-25 US US13/121,055 patent/US10407513B2/en not_active Expired - Fee Related
- 2009-09-25 LT LTEP09736624.9T patent/LT2334705T/lt unknown
- 2009-09-25 BR BRPI0918947A patent/BRPI0918947A2/pt active Search and Examination
- 2009-09-25 CN CN200980137520.4A patent/CN102164965B/zh not_active Expired - Fee Related
- 2009-09-25 CN CN201610114944.0A patent/CN105601745B/zh not_active Expired - Fee Related
- 2009-09-25 PL PL09736624T patent/PL2334705T3/pl unknown
- 2009-09-25 HU HUE09736624A patent/HUE033438T2/en unknown
- 2009-09-25 ES ES09736624.9T patent/ES2620603T3/es active Active
- 2009-09-25 DK DK09736624.9T patent/DK2334705T3/da active
- 2009-09-25 EA EA201100527A patent/EA201100527A1/ru unknown
- 2009-09-25 WO PCT/GB2009/002310 patent/WO2010035012A1/en active Application Filing
- 2009-09-25 PT PT97366249T patent/PT2334705T/pt unknown
- 2009-09-25 EP EP09736624.9A patent/EP2334705B1/en active Active
- 2009-09-25 CA CA2737241A patent/CA2737241C/en not_active Expired - Fee Related
-
2015
- 2015-07-03 JP JP2015134223A patent/JP2015178536A/ja active Pending
-
2017
- 2017-03-06 HR HRP20170374TT patent/HRP20170374T1/hr unknown
- 2017-03-14 CY CY20171100321T patent/CY1118713T1/el unknown
-
2019
- 2019-07-11 US US16/508,967 patent/US20200048372A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2737241C (en) | 2017-08-29 |
EP2334705B1 (en) | 2016-12-14 |
EA201100527A1 (ru) | 2011-10-31 |
BRPI0918947A2 (pt) | 2015-12-01 |
CA2737241A1 (en) | 2010-04-01 |
EP2334705A1 (en) | 2011-06-22 |
CN105601745B (zh) | 2020-09-08 |
US20200048372A1 (en) | 2020-02-13 |
PT2334705T (pt) | 2017-03-22 |
JP6063122B2 (ja) | 2017-01-18 |
JP2012503638A (ja) | 2012-02-09 |
CY1118713T1 (el) | 2017-07-12 |
CN105601745A (zh) | 2016-05-25 |
ES2620603T3 (es) | 2017-06-29 |
PL2334705T3 (pl) | 2017-06-30 |
US10407513B2 (en) | 2019-09-10 |
HUE033438T2 (en) | 2017-11-28 |
CN102164965B (zh) | 2016-03-30 |
HRP20170374T1 (hr) | 2017-05-05 |
WO2010035012A1 (en) | 2010-04-01 |
CN102164965A (zh) | 2011-08-24 |
US20110184152A1 (en) | 2011-07-28 |
LT2334705T (lt) | 2017-03-27 |
SI2334705T1 (sl) | 2017-05-31 |
WO2010035012A9 (en) | 2011-03-17 |
JP2015178536A (ja) | 2015-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11427650B2 (en) | Dual specificity antibody fusions | |
US20200048372A1 (en) | Biological Products | |
CA2773286C (en) | Disulfide stabilised multivalent antibodies | |
EP2776466B1 (en) | Albumin binding antibodies and binding fragments thereof |